ClearOne, Inc. (NASDAQ:CLRO) shares are down during Monday’s session. Last week, the company disclosed a merger agreement with Cortigent, Inc.

Merger Agreement With Cortigent: Key Details

ClearOne entered into a definitive merger agreement with Cortigent, a wholly-owned subsidiary of Vivani Medical. This deal is expected to close in the third quarter of 2026.

The deal includes a financing plan to raise between $10 million and $15 million, which aims to support the combined company’s operations.

As of March 31, the company’s cash and cash equivalents stood at $961 million.

ClearOne Business Update And Strategic Shift To Medtech

ClearOne is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential strategic transactions, managing and liquidating remaining assets of the company’s legacy operating business, collecting accounts receivable, and recovering prepaid assets. This merger with Cortigent is a significant step as it aims to pivot towards new growth opportunities in the medical technology space.

The merger is particularly relevant as Cortigent is developing advanced medical devices aimed at helping patients recover critical body functions, which aligns with ClearOne’s strategic shift from its previous business model. This move could potentially enhance ClearOne’s market position and open new revenue streams.

ClearOne (CLRO) Benzinga Edge Rankings: Momentum And Risk

Below is the Benzinga Edge scorecard for ClearOne, highlighting its strengths and weaknesses compared to the broader market:

  • Momentum: Bullish (Score: 84.54) — Stock is outperforming the broader market.

The Verdict: ClearOne’s Benzinga Edge signal reveals a momentum-driven story, suggesting strong short-term performance. However, the mixed signals from moving averages indicate that traders should remain cautious about potential volatility in the longer term.

CLRO Stock Price Moves After Merger News

CLRO Stock Price Activity: ClearOne shares are trading down 2.14% at $6.34 at the time of publication on Monday, according to Benzinga Pro data.

Photo via Shutterstock